Eight pharmaceutical companies will pay approximately $720 million in a settlement for their role in manufacturing opioid pills that fueled the ongoing nationwide epidemic of opioid addictions. New York Attorney General Letitia James announced Thursday that the state will receive up to $38.7 million of that money. The funds will help deliver critical resources to communities throughout New York and the nation to combat the opioid crisis. Payments will begin as soon as 2026.
The eight companies and the total amounts they will pay in funding to address the opioid crisis are:
- Mylan (now part of Viatris) will pay $284,447,916 over nine years;
- Hikma will pay $95,818,293 over one to four years;
- Amneal will pay $71,751,010 over 10 years;
- Apotex will pay $63,682,369 in a single year;
- Indivior will pay $38,022,450 over four years;
- Sun will pay $30,992,087 in one to four years;
- Alvogen will pay $18,680,162 in a single year; and
- Zydus will pay $14,859,220 in a single year.
File photo
